$0.47
-0.19 (-28.90%)
Open$0.56
Previous Close$0.66
Day High$0.59
Day Low$0.46
52W High$2.43
52W Low$0.46
Volume—
Avg Volume210.5K
Market Cap2.30M
P/E Ratio—
EPS$-1.47
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,426.5% upside
Current
$0.47
$0.47
Target
$16.55
$16.55
$10.07
$16.55 avg
$19.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 42.85M | 953.7K | 857.2K |
| Net Income | -7,051,802 | 90.7K | 81.5K |
| Profit Margin | -16.5% | 9.5% | 9.5% |
| EBITDA | -6,968,891 | 169.7K | 158.3K |
| Free Cash Flow | — | 104.6K | 58.4K |
| Rev Growth | +102.9% | +23.3% | +22.6% |
| Debt/Equity | — | 0.69 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |